Role of Dynamic Susceptibility Contrast Perfusion MRI in Glioma Progression Evaluation

Guanmin Quan; Kexin Zhang; Yawu Liu; Jia-Liang Ren; Deyou Huang; Weiwei Wang; Tao Yuan

doi:10.1155/2021/1696387

Role of Dynamic Susceptibility Contrast Perfusion MRI in Glioma Progression Evaluation

J Oncol. 2021 Feb 9:2021:1696387. doi: 10.1155/2021/1696387. eCollection 2021.

Authors

Guanmin Quan¹, Kexin Zhang¹, Yawu Liu², Jia-Liang Ren³, Deyou Huang⁴, Weiwei Wang⁵, Tao Yuan¹

Affiliations

¹ Department of Medical Imaging, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
² Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland.
³ GE Healthcare China, Beijing, China.
⁴ Department of Radiology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
⁵ Department of Radiology, Handan Central Hospital, Handan, China.

Abstract

Accurately and quickly differentiating true progression from pseudoprogression in glioma patients is still a challenge. This study aims to explore if dynamic susceptibility contrast- (DSC-) MRI can improve the evaluation of glioma progression. We enrolled 65 glioma patients with suspected gadolinium-enhancing lesion. Longitudinal MRI follow-up (mean 590 days, range: 210-2670 days) or re-operation (n = 3) was used to confirm true progression (n = 51) and pseudoprogression (n = 14). We assessed the diagnostic performance of each MRI variable and the different combinations. Our results showed that the relative cerebral blood volume (rCBV) in the true progression group (1.094, 95%CI: 1.135-1.636) was significantly higher than that of the pseudoprogression group (0.541 ± 0.154) (p < 0.001). Among the 18 patients who had serial DSC-MRI, the rCBV of the progression group (0.480, 95%CI: 0.173-0.810) differed significantly from pseudoprogression (-0.083, 95%CI: -1.138-0.620) group (p=0.015). With an rCBV threshold of 0.743, the sensitivity and specificity for discriminating true progression from pseudoprogression were 76.5% and 92.9%, respectively. The Cho/Cr and Cho/NAA ratios of the true progression group (2.520, 95%CI: 2.331-2.773; 2.414 ± 0.665, respectively) were higher than those of the pseudoprogression group (1.719 ± 0.664; 1.499 ± 0.500, respectively) ((p=0.001), (p < 0.001), respectively). The areas under ROC curve (AUCs) of enhancement pattern, MRS, and DSC-MRI for the differentiation were 0.782, 0.881, and 0.912, respectively. Interestingly, when combined enhancement pattern, MRS, and DSC-MRI variables, the AUC was 0.965 and achieved sensitivity 90.2% and specificity 100.0%. Our results suggest that DSC-MRI can significantly improve the diagnostic performance for identifying glioma progression. DSC-MRI combined with conventional MRI may promptly distinguish true gliomas progression from pseudoprogression when the suspected gadolinium-enhancing lesion was found, without the need for a long-term follow-up.

Publication types

Review